September 25, 2013
Chugai Pharmaceutical announced on September 20 that it has received on the same day approval for its antibody-drug conjugate (ADC) Kadcyla Intravenous Infusion 100 mg/160 mg (trastuzumab emtansine (recombinant)) for the treatment of HER2-positive inoperable or relapsed breast cancer. Kadcyla...read more